Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models
International Journal of Molecular Sciences · 30.11.2023 · 24 (23) · 17015
DOI: 10.3390/ijms242317015 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.11.2023. Verfasst von Julia Raitanen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Research Promotion Agency, Open Access Funding.
Abstract (Originalsprache)
In vitro therapeutic efficacy studies are commonly conducted in cell monolayers. However, three-dimensional (3D) tumor spheroids are known to better represent in vivo tumors. This study used [177Lu]Lu-PSMA-I&T, an already clinically applied radiopharmaceutical for targeted radionuclide therapy against metastatic castrate-resistant prostate cancer, to demonstrate the differences in the radiobiological response between 2D and 3D cell culture models of the prostate cancer cell lines PC-3 (PSMA negative) and LNCaP (PSMA positive). After assessing the target expression in both models via Western Blot, cell viability, reproductive ability, and growth inhibition were assessed. To investigate the geometric effects on dosimetry for the 2D vs. 3D models, Monte Carlo simulations were performed. Our results showed that PSMA expression in LNCaP spheroids was highly preserved, and target specificity was shown in both models. In monolayers of LNCaP, no short-term (48 h after treatment), but only long-term (14 days after treatment) radiobiological effects were evident, showing decreased viability and reproductive ability with the increasing activity. Further, LNCaP spheroid growth was inhibited with the increasing activity. Overall, treatment efficacy was higher in LNCaP spheroids compared to monolayers, which can be explained by the difference in the resulting dose, among others.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria.
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria.
- Vienna Doctoral School of Chemistry (DoSChem), University of Vienna, 1090 Vienna, Austria.
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria.
- Department of Radiation Oncology, Division of Medical Radiation Physics, Medical University of Vienna, 1090 Vienna, Austria.
- Joint Applied Medicinal Radiochemistry Facility, Medical University of Vienna, University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Julia Raitanen, Hermann Fuchs, Marcus Hacker, Theresa Balber, Dietmar Georg
Förderung
- Austrian Research Promotion Agency
- Open Access Funding
Zitieren
APA
Raitanen, J., Barta, B., Fuchs, H., Hacker, M., Balber, T., Georg, D., & Mitterhauser, M. (2023). Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models. International Journal of Molecular Sciences, 24(23), 17015. https://doi.org/10.3390/ijms242317015
Vancouver
Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D, et al. Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models. International Journal of Molecular Sciences. 2023;24(23):17015. doi:10.3390/ijms242317015
BibTeX
@article{Raitanen2023,
author = {Raitanen, Julia and Barta, Bernadette and Fuchs, Hermann and Hacker, Marcus and Balber, Theresa and Georg, Dietmar and Mitterhauser, Markus},
title = {Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {23},
pages = {17015},
doi = {10.3390/ijms242317015}
}
EUVIMED